Gérard Zalcman, MD, PhD, on Non–Small Cell Lung Cancer: Phase III Trial Findings on Nivolumab and Ipilimumab

ESMO Congress 2022


Gérard Zalcman, MD, PhD, of France’s Bichat-Claude Bernard Hospital, Assistance Publique–Hôpitaux de Paris, discusses phase III results from the IFCT-1701 trial, which explored the questions of whether to administer nivolumab plus ipilimumab for 6 months or whether to prolong the treatment in patients with advanced non–small cell lung cancer (Abstract 972O).


Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Currently there is no solid evidence to justify the duration of immunotherapy in the non-small cell lung cancer. In phase one trials, the duration was set without any limit until progression or toxicity. Then it was set to five years, then two years, but again, without randomized data to justify such duration. The DICIPLE phase three trial, also entitled IFCT-1701, has had the goal to look whether a shorter duration of immunotherapy by Nivo plus Ipilimumab would be as efficient as a longer one, two years, in non-small cell lung cancer, in first-line setting. So we randomized the non-small cell lung cancer patients, metastatic patients, PS01, aged 18 to 75, with measurable disease, any PDL1 into an induction treatment by Nivo plus Ipilimumab for six months at classical dosing. And at six months, we randomized patients with disease control into a continuation arm with the standard immunotherapy, or a stop-and-go arm, where the immunotherapy was stopped, the patient were observed, and the resume immunotherapy in case of progression. Of course, in the two arm, the follow up intervals were the same. We accrued 265 patients, treated 261, but only randomized 71 patients because most of the patients progressed or exhibit toxicity precluding continuation. And unfortunately, we had to stop the trail because the Nivo plus Ipil combo will not be registered or nor reimbursed in Europe. But, the results were striking because the median PFS in the continuation arm was 20.8 months, as compared with 35 months in the stop-and-go arm. The OS results show, again, there was no deleterious effect to stop early the immunotherapy, with 18 months OS rates of 79% in the continuation arm and 94% in the stop-and-go arm. Furthermore, there were tenfold less grade three, four adverse events in the stop-and-go arm. So these results are hypothesis-generating because of the lack of statistical power, but are very provocative. And we have launched another randomized, phase three clinical trial with the very same design, meaning randomization at six months in patients with disease control, but after induction by chemo-immunotherapy. And again, it will be a non-inferiority trial. This trial is the DIAL trial, which began on March '22.

Related Videos

Kidney Cancer

Toni K. Choueiri, MD, and Laurence Albiges, MD, PhD, on RCC: Review of Two Key Abstracts on Belzutifan Plus Cabozantinib and Pembrolizumab Plus Lenvatinib

Toni K. Choueiri, MD, of the Dana-Farber Cancer Institute, and Laurence Albiges, MD, PhD, of France’s Gustave Roussy Cancer Centre, discuss results from two important trials presented at ESMO 2022: Cohort 1 of the LITESPARK-003 study of belzutifan plus cabozantinib as first-line treatment of advanced renal cell carcinoma (RCC), and the KEYNOTE-B61 study of pembrolizumab plus lenvatinib as first-line treatment for non–clear cell RCC (Abstracts 1447O and 1448O).

Prostate Cancer

Neal D. Shore, MD, on Prostate Cancer: Biomarker Analysis, Enzalutamide, and Active Surveillance

Neal D. Shore, MD, of Carolina Urologic Research Center/Genesis Care, discusses new data from the ENACT trial, which showed that patients with prostate cancer and the RNA biomarkers PAM50 and AR-A were likely to have better outcomes with enzalutamide treatment. The results suggest that such RNA biomarkers may help to identify patients who may benefit from enzalutamide treatment compared with active surveillance (Abstract 1385P).

Gynecologic Cancers

Ana Oaknin, MD, PhD, on Cervical Cancer: New Findings on Cemiplimab in Recurrent or Metastatic Disease

Ana Oaknin, MD, PhD, of Barcelona’s Vall d’Hebron University Hospital, discusses an analysis of long-term survival from the EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trial. Cemiplimab-rwlc is the first immunotherapy to demonstrate an overall survival benefit as a second-line monotherapy for patients with recurrent or metastatic cervical cancer previously treated with platinum-based chemotherapy but not immunotherapy. The benefit was sustained in this population (Abstract 519MO).

Kidney Cancer

Axel Bex, MD, PhD, on Renal Cell Carcinoma: Phase III Results With Atezolizumab as Adjuvant Therapy

Axel Bex, MD, PhD, of the Netherlands Cancer Institute, discusses phase III findings from the IMmotion010 study, which evaluated the efficacy and safety of atezolizumab vs placebo in patients with renal cell cancer who are at high risk of disease recurrence following nephrectomy (Abstract LBA66).

Lung Cancer

Charles Swanton, PhD, on Non–Small Cell Lung Cancer Induced by Air Pollution

Charles Swanton, PhD, of The Francis Crick Institute, discusses a newly discovered mechanism of action for air pollution–induced non–small cell lung cancer in which particles linked to climate change appear to promote cancerous changes. The finding might pave the way for new potential approaches to lung cancer prevention and treatment (Abstract LBA1).